Allarity Therapeutics (NASDAQ:ALLR) vs. ADMA Biologics (NASDAQ:ADMA) Head to Head Analysis

ADMA Biologics (NASDAQ:ADMA – Get Free Report) and Allarity Therapeutics (NASDAQ:ALLR – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, analyst recommendations, profitability, institutional ownership and earnings.

Profitability

This table compares ADMA Biologics and Allarity Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ADMA Biologics 35.14% 42.56% 26.96%
Allarity Therapeutics N/A -152.77% -46.50%

Analyst Ratings

This is a breakdown of current recommendations and price targets for ADMA Biologics and Allarity Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ADMA Biologics 0 3 3 0 2.50
Allarity Therapeutics 1 0 1 0 2.00

ADMA Biologics presently has a consensus target price of $17.50, indicating a potential upside of 29.99%. Allarity Therapeutics has a consensus target price of $10.25, indicating a potential upside of 1,071.16%. Given Allarity Therapeutics’ higher possible upside, analysts plainly believe Allarity Therapeutics is more favorable than ADMA Biologics.

Volatility and Risk

ADMA Biologics has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500. Comparatively, Allarity Therapeutics has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500.

Valuation & Earnings

This table compares ADMA Biologics and Allarity Therapeutics”s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ADMA Biologics $519.15 million 5.75 $146.93 million $0.77 17.48
Allarity Therapeutics $320,000.00 43.51 -$11.23 million ($0.98) -0.89

ADMA Biologics has higher revenue and earnings than Allarity Therapeutics. Allarity Therapeutics is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

75.7% of ADMA Biologics shares are held by institutional investors. Comparatively, 11.5% of Allarity Therapeutics shares are held by institutional investors. 3.9% of ADMA Biologics shares are held by company insiders. Comparatively, 0.2% of Allarity Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

ADMA Biologics beats Allarity Therapeutics on 11 of the 13 factors compared between the two stocks.

About ADMA Biologics

(Get Free Report)

ADMA Biologics is a biopharmaceutical company that develops, manufactures and markets plasma-derived therapies for people with immune deficiencies and certain infectious diseases. Its products include BIVIGAM and ASCENIV, intravenous immune globulin therapies used to treat primary humoral immunodeficiency, and Nabi-HB, an immune globulin used for hepatitis B prevention in specific clinical settings. The company collects human plasma through its U.S. donor centers and processes it into therapies at its manufacturing facility in Boca Raton, Florida.

About Allarity Therapeutics

(Get Free Report)

Allarity Therapeutics is a biotechnology company focused on developing precision-medicine treatments for cancer. Its approach combines oncology drug development with tools intended to help identify patients who may be more likely to respond to a particular therapy. The company’s Drug Response Predictor (DRP) technology analyzes gene-expression data to estimate how a patient’s tumor may respond to a drug. Allarity has developed the platform for use in selecting patients for clinical studies and as a potential companion diagnostic.

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.